You can buy or sell ADAP and other stocks, options, ETFs, and crypto commission-free!
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Read More The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
52 Week High
52 Week Low
Traders Sift Through Virtual Cancer Meeting’s Winners and Losers
(Bloomberg) -- Biotechnology stocks saw broad swings Friday morning as investors worked their way through a deluge of data from cancer drug developers presentin
BRIEF-Spear T-Cells Targeting Mage-A4 Demonstrate New Responses In Esophagogastric Junction (Egj), Lung, And Head And Neck Cancers
May 29 (Reuters) - Adaptimmune Therapeutics PLC: * SPEAR T-CELLS TARGETING MAGE-A4 DEMONSTRATE NEW RESPONSES IN ESOPHAGOGASTRIC JUNCTION (EGJ), LUNG, AND HEAD
— per share
Expected Jul 30, Pre-Market